Heart failure & cardiomyopathies
Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial
Study context
- Population
- Adults with symptomatic HF (NYHA II–III), left ventricular ejection fraction (LVEF) ≤35% and left bundle branch block (LBBB) (QRS ≥130 ms)
- Participants
- 179 adults
- Planned comparison
- Conduction system pacing vs biventricular resynchronization
- Primary endpoint
- Hierarchy of:
- All-cause death
- Any HF hospitalization
- Any urgent HF visit
- Change in LVEF from baseline
- Follow-up
- 12 months postprocedure
Methodological detailsrationale and design, investigator-led, multicentre, non-inferiority, 1:1 randomisation, Enrollment November 2022 to December 2023, Key secondary endpoint: mean total direct medical cost per patient
- Rationale and design
- Investigator-led
- Multicentre
- Non-inferiority
- 1:1 randomisation
- Enrollment November 2022 to December 2023
- Key secondary endpoint: mean total direct medical cost per patient
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial. Am Heart J. Published 3 June 2025. doi:10.
Summarised from the published abstract; every number is checked against it